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Lipid A structure and immunoinhibitory effect of the marine 
bacterium Cobetia pacifica KMM 3879T 
Flaviana Di Lorenzo,*[a] Angelo Palmigiano,[b] Sami Albitar-Nehme,[c] Mateusz Pallach,[a] Maxim 
Kokoulin,[d] Nadezhda Komandrova,[d] Lyudmila Romanenko,[d] Maria Lina Bernardini,[c] Domenico 
Garozzo,[b] Antonio Molinaro,[a] Alba Silipo*[a] 
 
Abstract: The structural elucidation of lipopolysaccharides (LPSs) 
from Gram-negative marine bacteria, in addition to the assessment of 
their immunological properties, is a fascinating and active research 
field, not only because it can give insight to aid understanding of 
adaptation phenomena occurring in the marine environment but also 
it opens new perspectives of design and development of novel 
immunoregulatory drugs. Here we report the structural 
characterization of the lipid A component of the LPS isolated from the 
marine bacterium Cobetia pacifica KMM 3879T, characterized by a 
family of species differing in the acylation pattern. The structure has 
been achieved by extensive chemical analyses and matrix-assisted 
laser desorption/ionization (MALDI) mass spectrometry. Moreover, 
cellular immunology studies on the LPS highlighted its low 
immunostimulatory impact and a very interesting and promising 
inhibitory activity of the toxic effects of Escherichia coli LPS. 
Introduction 
Marine bacteria have adapted, over millions of years, to survival 
in adverse conditions as marine environments are often 
characterized by one or more extreme chemical or physical 
parameters, such as high salinity, low temperature and elevated 
pressure.[1] The adaptation process has been accomplished by 
developing several and complex processes involving modification 
of cell structural components (i.e. proteins, nucleic acids, 
membrane lipids) in order to assure a shield from the disrupting 
action of natural stress factors. Therefore, most of the structural 
peculiarities observed for bacterial components can be seen as a 
response to the evolutionary pressure exerted by the marine 
environment.[1]  
Gram-negative bacteria are widespread in marine habitats, of 
which constitute a considerable part of the microbial community. 
A hallmark of most of Gram-negative bacteria is their asymmetric 
outer membrane whose surface is mostly covered by 
lipopolysaccharides (LPS), which are in direct contact with the 
external environment and, as such, play an important role in 
protection towards the outside dangerous agents.[2] In addition to 
their fundamental structural function in contributing to the cell 
homeostasis by affecting cellular rigidity and permeability, LPSs 
are involved in many aspects of host–bacterium interaction 
events such as, among others, colonization, symbiosis and 
virulence.[3-5] Importantly, in mammals, LPS is specifically 
recognized by the innate immune receptor complex constituted by 
Toll-like receptor 4 (TLR4) and myeloid differentiation protein-2 
(MD-2).[3-5] As a consequence of the recognition event, a rapid 
release of pro-inflammatory cytokines, which in turn regulates 
adaptive immune responses, is typically triggered.[3-6] The 
immunopotential of an LPS is strictly structure-related: there are 
LPS molecules acting as agonists of TLR4/MD-2 receptorial 
complex, activating the pro-inflammatory response, whereas 
others, in a structure dependent fashion, can moderately activate 
the immune response or can even antagonize the binding of toxic 
LPS to the immune receptor complex.[3-6] Given the above, the 
search for new LPS derivatives, that can be used as 
immunomodulatory compounds in a perspective of drug synthesis 
and development, is increasingly growing.[7]  
LPSs consist of three different domains: a glycolipid part, 
termed lipid A, an oligosaccharide part termed core (core OS) and 
a highly variable polysaccharide moiety, designated as the O-
chain, that is the outermost portion of the macromolecule.[3-7] In 
the case of absence of the O-chain, the LPS is termed rough-type 
LPS (R-LPS), whereas when expressing all moieties, is 
designated as smooth-type LPS (S-LPS).[3-6,8,9] Since the 
structure of LPS is strongly influenced by the physiological 
conditions of the surrounding environment, it is reasonable to 
assume that marine bacteria can colonize a hostile habitat by 
modifying their LPS structure in order to reinforce the membrane 
and to assure protection and proliferation.[8] Therefore, LPSs 
showing unusual chemical characteristics are expected for 
marine bacteria. Within this frame, LPSs expressing uncommon 
structural features are taken in consideration as potential 
antagonists of MD-2/TLR4 receptorial complex.[8,9] 
The present study is focused on the LPS from Cobetia pacifica 
KMM 3879T, a marine bacterium isolated from a sandy sediment 
(depth 1 m) sample collected from the shore of the Sea of Japan 
(Russia). We have previously established that this bacterium 
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expresses an S-LPS with an uncommon O-chain structure made 
up of a trisaccharide repeating unit containing rhamnose, 3-O-
sulphate-D-glucose and 3-O-sulphate-D-galactose.[10] Here we 
describe the structural characterization of the lipid A moiety that 
turned out to be a complex mixture of variously acylated species. 
Moreover, a detailed investigation of the C. pacifica KMM 3879T 
LPS pro-inflammatory activity, on both human and murine cell 
lines, was performed, clearly demonstrating its weak agonistic 
activity and its inhibitory effect against potent agonist LPS. 
Results and Discussion 
Isolation and fatty acid compositional analysis of the lipid A 
isolated from C. pacifica KMM 3879T LPS. 
 
The LPS was extracted from dried bacterial pellet through the 
hot phenol/water procedure.[11] The nature and relative purity of 
the extracted material was established through SDS-PAGE after 
silver nitrate gel staining[12] which showed a ladder-like profile in 
the upper part of the gel typical of an S-LPS (Figure S1).[10] To 
remove cell contaminants, such as proteins and nucleic acids, the 
extracted LPS was subjected to an extensive enzymatic digestion 
followed by dialysis and ultracentrifugation. A further step of 
purification by size-exclusion chromatography was also executed.  
A set of chemical analyses, both to determine the sugar and 
lipid content, was executed on an aliquot of pure LPS. 
Monosaccharide analysis confirmed the occurrence, as main 
species, of rhamnose, galactose and glucose, in agreement with 
our previous data.[10] Investigation of the total fatty acid content 
revealed the occurrence mainly of (R)-3-hydroxydodecanoic acid 
((R)-12:0 (3-OH)), dodecanoic (12:0) and decanoic (10:0) acids. 
In minor amounts, (R)-3-hydroxydecanoic acid ((R)-10:0 (3-OH)), 
(R)-3-hydroxyundecanoic acid ((R)-11:0 (3-OH)), (R)-3-
hydroxytridecanoic acid ((R)-13:0 (3-OH)), undecanoic acid (11:0) 
and tridecanoic acid (13:0) were also identified.     
 
MALDI Mass Spectrometry (MS) investigation of the lipid A 
from C. pacifica KMM 3879T LPS. 
 
In order to define the lipid A structure in detail, an aliquot of the 
pure LPS was subjected to a mild acid hydrolysis with acetate 
buffer, typically used to selectively cleave the labile glyosidic 
linkage between the core OS and the non-reducing glucosamine 
of the lipid A domain. In parallel, the lipid A micro-extraction 
procedure following the El Hamidi et al. approach[13] (referred to 
here on as micro-extracted lipid A) on lyophilized bacterial pellet 
was also performed.   
A meticulous MALDI MS and MS/MS analysis was executed 
both on the mild acid hydrolysis product and the micro-extracted 
lipid A. The reflectron MALDI mass spectrum, recorded in 
negative polarity, of the micro-extracted lipid A is reported in 
Figure 1; it showed a complex pattern of peaks relative to 
deprotonated [M-H]- lipid A species differing in the number and 
the nature of fatty acids and in phosphate content. The 
heterogeneity of C. pacifica KMM 3879T lipid A structure was 
visible since most of the main peaks were characterized by the 
occurrence of mass differences of 28 amu (-CH2CH2- unit) which 
are diagnostic for lipid A species differing in the length of their acyl 
chains, also in accordance to compositional analysis data. Three 
distinct sets of peaks around m/z 1628.0, 1473.9, 1275.7 were 
clearly detected (Figure 1) and matched with hexa-acylated, 
penta-acylated and tetra-acylated lipid A species carrying 12:0 (3-
OH), 12:0 and 10:0 as acyl moieties. In detail, the ion at m/z 
1628.0 was assignable to a bis-phosphorylated hexa-acylated 
lipid A species carrying four 12:0 (3-OH) units, one 12:0 and one 
10:0 fatty acids. The relative mono-phosphorylated lipid A species 
was also attributed to the peak at m/z 1548.0. In the mass range 
m/z 1349.9-1473.9, penta-acylated lipid A species were identified: 
the peak at m/z 1473.9 matched with a bis-phosphorylated penta-
acylated lipid A form carrying four 12:0 (3-OH) residues and one 
12:0; the peak at m/z 1429.9 was assignable to a different penta-
acylated lipid A species decorated by two phosphate groups and 
carrying three 12:0 (3-OH) units, one 12:0 and one 10:0. The 
corresponding mono-phosphorylated penta-acylated forms were 
also present at m/z 1393.9 and 1349.9 respectively. Finally, tetra-
acylated lipid A species, mono- or bis-phosphorylated, lacking 
one 12:0 (3-OH) with the respect to penta-acylated species (m/z 
1473.9), were also detected. 
The negative-ion MALDI mass spectrum of the product isolated 
by mild acid treatment (not shown) appeared identical to that 
achieved by the micro-extraction procedure.  A detailed negative-
ion MS/MS analysis on several ion peaks of the mild acid 
treatment product was performed to unveil the location of the lipid 
A acyl moieties with respect to the glucosamine disaccharide 
backbone. In detail, MS/MS spectrum of the precursor ion at m/z 
1628.0 (Figure 2), relative to the bis-phosphorylated hexa-
acylated species, clearly showed an intense peak at m/z 1411.9 
corresponding to an ion originated from the loss of a 12:0 (3-OH) 
fatty acid. A further intense peak, at m/z 1313.9, was assigned to 
a fragment lacking both one phosphate unit and one 12:0 (3-OH) 
fatty acid. Less intense peaks were also observed at m/z 1427.9 
and 1211.8 and were assigned to fragments originated from the 
loss of a 12:0 fatty acid (m/z 1427.9) and both of one 12:0 (3-OH) 
and one 12:0 (m/z 1211.8) fatty acids. The presence of the last 
peak and the concurrent absence of peaks corresponding to 
fragments originated from a loss of a hydroxylated fatty acid 
bearing a secondary acyl substituent indicates that secondary 
fatty acids are linked to the acyloxyacyl amides. The ion 
originating from the cleavage of the glycosydic linkage of the 
glucosamine backbone (Y1)[14] was pivotal to confirm the acyl 
chains distribution with the respect to the disaccharide backbone. 
Indeed, peak at m/z 808.5 was crucial to prove that the 10:0 unit 
was a secondary acyl substituent decorating only the reducing 
glucosamine which also carried two 12:0 (3-OH) moieties and one 
phosphate. The MS/MS analysis of the precursor ion at m/z 
1473.9 (Figure S2) confirmed the assignment to a bis-
phosphorylated penta-acylated lipid A species expressing four 
12:0 (3-OH) as primary fatty acids, and one 12:0 as secondary 
acyl substituent; this hypothesis was supported by the occurrence 
of the product ions at m/z 1257.7 and 1274.7 corresponding to 
lipid A fragments produced from the loss of one 12:0 (3-OH) and 
one 12:0 fatty acid, respectively (Figure S2). The fragment ion 
observed at m/z 1159.7 was correlated to a fragment devoid of 
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both one phosphate and one 12:0 (3-OH) fatty acid. Interestingly, 
besides the above mentioned Y1 ion (m/z 654.3), a further peak, 
originating from the sugar ring fragmentation (0,4A2)[14] at m/z 
878.5, was also detected. Both Y1 and 0,4A2 ions were again 
fundamental to confirm the fatty acids distribution with the respect 
to the glucosamine backbone. In particular, the 0,4A2 ion was 
crucial not only to confirm the nature of the primary acyl chains 
decorating the reducing glucosamine unit (namely two 12:0 (3-
OH)) but also to clearly locate the secondary acyl chain 12:0 at 
the non-reducing glucosamine unit. Finally, the negative-ion 
MS/MS spectrum of the precursor ion at m/z 1275.7 (Figure 3), 
relative to a bis-phosphorylated lipid A species carrying three 12:0 
(3-OH) and one 12:0, showed peaks at m/z 1075.5, 1059.5 and 
961.5 relative to lipid A fragments devoid of one 12:0 (m/z 1075.5), 
one 12:0 (3-OH) (m/z 1059.5), one 12:0 (3-OH) and one 
phosphate unit (m/z 961.5). Moreover, it showed the important 
peak at m/z 654.3 corresponding to the Y1 ion that, as previously 
mentioned, confirmed that the reducing glucosamine carries two 
12:0 (3-OH) residues. 
In order to unequivocally establish the secondary fatty acids 
composition and position, an aliquot of lipid A was subjected to 
ammonium hydroxide hydrolysis.[15] The MALDI mass spectrum 
(Figure 4), recorded in negative polarity, of the ammonium treated 
lipid A showed ion peaks in the m/z range of 997.6-1349.4 that 
could be assigned as follows: the ion at m/z 1151.7 was explained 
as a mono-phosphorylated tetra-acyl residue made up of both the 
primary amide-linked 12:0 (3-OH) carrying the secondary 10:0 
and 12:0 units; the ion at m/z 997.6 was identified as the mono-
phosphorylated tri-acyl residue composed of the N-linked 12:0 (3-
OH) units and one 12:0 (Figure 4). Minor peaks at m/z 1195.7 and 
1275.7 were assigned to mono-phosphorylated (m/z 1195.7) and 
bis-phosphorylated (m/z 1275.7) tetra-acyl lipid A made up of 
three 12:0 (3:OH) and one 12:0. Similarly, peak at m/z 1231.6 was 
identified as the bis-phosphorylated tetra-acyl residue composed 
of the two amide-linked 12:0 (3-OH) units carrying the 10:0 and 
12:0 secondary acyl substituents, whereas peak at m/z 1349.8 
accounted for the mono-phosphorylated penta-acylated form 
decorated by three 12:0 (3-OH), one 10:0 and 12:0. The negative 
ion MS/MS analysis of precursor ions at m/z 1151.7 and 997.6 
univocally established the location of the secondary acyl 
substituents (Figures 5 and S3). Briefly, the MS/MS spectrum of 
precursor ion at m/z 1151.7 (Figure 5) clearly showed ions at m/z 
951.6 and 979.6 relative to lipid A fragments devoid of 12:0 and 
10:0 fatty acid respectively. More interestingly, ions 0,2A2 and 0,2A1 
at m/z 740.4 and 200.0, respectively, proved the exact location of 
the secondary acyl substitution 12:0 as occurring exclusively on 
the primary amide-bound fatty acid of the non-reducing 
glucosamine. This specularly further proved the nature of the 10:0 
as the secondary fatty acid of the acyloxyacyl amide moiety of the 
reducing glucosamine. This structural assignment was further 
confirmed by the negative-ion MS/MS analysis of the precursor 
ion at m/z 997.6 whose spectrum is reported in Figure S3.  
Thus, by merging MS and MS/MS data of the micro-extracted lipid 
A, the mild acid hydrolysis and the ammonium hydroxide-treated 
products with the compositional analysis, it was possible to define 
the C. pacifica KMM 3879T LPS as expressing a complex blend 
of lipid A species whose component with the highest acylation 
degree is shown in Figure 6. The anomeric configuration of both 
glucosamine units was not determined and is sketched in Figure 
6 as following literature data on previously characterized lipid A 
structures. 
 
Immunological properties of C. pacifica KMM 3879T LPS. 
 
We examined the effect of C. pacifica KMM 3879T LPS on both 
the human and murine innate immune system in vitro.  
First, we tested the immunopotential of C. pacifica KMM 3879T 
LPS through its analysis in mouse (C57BL/6) bone marrow 
derived macrophages (BMDMs). BMDMs were exposed to 
different C. pacifica KMM 3879T LPS concentrations (1, 10, and 
100 ng/mL) for 6 h. The potent agonist LPS from E. coli O111:B4 
was used as a positive control in parallel, as above. Unstimulated 
cells were as negative control. The measurement of the release 
of Tumor necrosis factor-α (TNF-α) was the read-out of this 
experiment. As shown in Figure 7a, the C. pacifica KMM 3879T 
LPS caused a lower release of TNF-α compared to E. coli LPS (C. 
pacifica KMM 3879T LPS vs. E. coli LPS p < 0.05 at 100 ng/mL; p 
< 0.01 at 1 ng/mL; p < 0.001 at 10 ng/mL), thus indicating a weak 
capability to elicit an inflammatory response in murine 
macrophages. 
Since it is known that the human TLR4/MD-2 complex is more 
sensitive to detect and discriminate among the different LPS 
species than the murine TLR4/MD-2, to establish whether human 
monocytes are more sensitive than BMDMs to C. pacifica KMM 
3879T LPS, we used human peripheral blood mononuclear cells 
(PBMC) in a stimulation assay. Cells were stimulated for 18 h with 
LPS of C. pacifica KMM 3879T at concentrations of 10 ng/mL, 1 
ug/mL and 10 ug/mL or E. coli O111:B4 at concentrations of 1, 10 
and 100 ng/mL. As above, release of the inflammatory cytokine 
TNF-α was quantified. Low amounts of TNF-α were detected with 
the LPS of C. pacifica KMM 3879T, whereas LPS of E. coli 
induced a significantly high release of this cytokine (C. pacifica 
KMM 3879T LPS vs. E. coli LPS p < 0.01 at 10 µg/mL; p < 0.001 
at 100 ng/mL and 1 µg/mL) (Figure 7b).  
The low immunological properties of C. pacifica KMM 3879T 
LPS were also assessed in the model of HEK293 cells stably 
expressing human CD14, MD-2, and human TLR4. HEK 293 
hTLR4 cells were stimulated with different C. pacifica KMM 3879T 
LPS concentrations (1, 10, and 100 ng/mL). Likewise, the LPS 
from E. coli O111:B4 was employed at the same concentrations. 
Activation of NF-κB (Nuclear Factor kappa B) and CXCL-8 
(Chemokine ligand 8) production were the read-out of this 
experiment. The luciferase assay results showed that the C. 
pacifica KMM 3879T LPS induced a significantly lower NF-κB 
activation with respect to cells treated with E. coli LPS (C. pacifica 
KMM 3879T LPS vs. E. coli LPS p < 0.01 at 10 ng/mL; p < 0.001 
at 1 ng/mL and 100 ng/mL) (Figure 8a). In accordance with this 
result, CXCL-8 production was lower after stimulation with C. 
pacifica KMM 3879T LPS with respect to LPS from E. coli LPS (C. 
pacifica KMM 3879T LPS vs. E. coli LPS p < 0.01 at 1 ng/mL; p < 
0.001 at 10 ng/mL and 100 ng/mL) (Figure 8b). 
Since some LPS isolated from marine bacteria have been 
reported to exhibit a fascinating potential as inhibitors of 
endotoxically active LPS, we next proceeded to evaluate the 
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ability of C. pacifica KMM 3879T LPS to interfere with the TLR4-
mediated signaling triggered by E. coli LPS. To assess this 
capability, HEK 293-hTLR4 cells were pre-incubated for 1 h with 
different amounts (1, 10, and 100 ng/mL) of C. pacifica KMM 
3879T LPS and then exposed to 10 ng/mL of E. coli LPS for 4 h 
(Figure 9). NF-κB activation and CXCL-8 production were the 
read-out of this experiment. The results clearly showed that C. 
pacifica KMM 3879T LPS significantly inhibited E. coli LPS-
dependent TLR4-mediated NF-κB activation as well as CXCL-8 
production at all the concentrations tested (NF-κB activation, C. 
pacifica KMM 3879T LPS vs. E. coli LPS p < 0.01 at 10 ng/mL and 
100 ng/mL; p < 0.001 at 1 ng/mL; CXCL-8 production, C. pacifica 
KMM 3879T LPS vs. E. coli LPS p < 0.001 at 1 ng/mL). 
Interestingly, when HEK 293-hTLR4 cells were pre-incubated with 
the lowest concentration of C. pacifica KMM 3879T LPS (1 ng/mL) 
and then exposed to 10 ng/mL of E. coli LPS, the inhibitory activity 
of the marine bacterium LPS resulted in higher measurements for 
both the NF-κB and CXCL-8 levels. 
A similar competition assay, by stimulating PBMC with different 
amounts (100 ng/mL, 1 and 10 µg/mL) of C. pacifica KMM 3879T 
LPS and then exposed to 10 ng/mL of E. coli LPS, was also 
performed (Figure S4). The latter competition assay further 
confirmed the inhibitory properties of C. pacifica KMM 3879T LPS 
with regards to the E. coli LPS toxicity on human macrophages.  
All these data clearly suggest that C. pacifica KMM 3879T LPS 
acts as a very weak immunostimulant agent on both human and 
murine immune cells. Intriguingly, it also exhibits a good 
TLR4/MD-2 inhibitory activity towards the potent agonist LPS at 
all the concentrations used in the assays. 
 
Conclusions 
 
Marine bacteria represent a basin of biodiversity able to furnish 
intriguing biological activities to be investigated. The hostile 
environmental conditions that marine bacteria face render them a 
promising source of human non-toxic compounds that can be 
potentially used for clinical applications.[7] Within this frame, 
several potential therapeutics based on modified LPSs have 
entered clinical trials to examine their ability to reduce 
inflammatory LPS-triggered symptoms.[16,17] The observation of 
very weak or no immunostimulatory effects exerted by some LPSs 
isolated from marine bacteria, in addition to the never-ending 
reservoir from which such microorganisms can be isolated, 
indubitably make them potential targets to employ for bio-inspired 
therapies against LPS-induced sepsis and septic shock.[8,16] In 
view of this, here we showed the structural characterization of the 
lipid A isolated from the marine bacterium C. pacifica KMM 3879T 
LPS, executed by MALDI MS and MS/MS investigation on the 
lipid A directly isolated from cells through the El Hamidi et al 
protocol,[12] and on the lipid A obtained after mild acid treatment 
on the pure LPS..  
The C. pacifica KMM 3879T LPS exhibited a heterogenous lipid 
A with penta-acylated species as the main forms, decorated by 
one or two phosphate groups. Briefly, two penta-acylated species 
have been detected, differing in the acylation pattern: i) one lipid 
A species was constituted by four (R)-12:0 (3-OH) and one 12:0, 
ii) whereas the other was decorated by three (R)-12:0 (3-OH), one 
10:0 and one 12:0. In addition to such heterogeneity, a further 
variability in the fatty acid chain length for each species has been 
observed. Hexa-acylated lipid A species carrying a further 
secondary acyl chain, as well as tetra-acylated forms were also 
detected. Therefore, the structural elucidation further confirmed 
the general tendency of marine bacteria lipid As to express 
shorter acyl chains [10:0, 12:0, 12.0 (3-OH)] with respect to those 
isolated from other bacterial strains, like Enterobacteriaceae.[8] 
This shortening of the lipid A acyl chains can be considered as an 
evolutionary adaptation stratagem of the bacterial cell envelope 
to resist to environmental stress factors, since short lipids have 
less Van der Waals interactions between the chains, compared to 
long chain fatty acids, thus preserving the required fluidity of the 
membrane to survive in the variable marine habitat.[8,10]  
Analogously, the sulfate groups decorating the O-chain structure 
of C. pacifica KMM 3879T might act as a buffering system to 
regulate the pH on the external membrane surface, thus providing 
protection to the bacterium against the environmental salinity 
conditions.[8,10] 
The establishment of the structure of the lipid A from C. pacifica 
KMM 3879T prompted us to screen its immunological properties 
on TLR4/MD-2 complex both in human and murine systems. The 
immunological studies clearly demonstrated the very weak 
capability of C. pacifica KMM 3879T LPS in eliciting an immune 
response, as shown by the significantly low release of pro-
inflammatory cytokines in murine BMDMs and upon human TLR4 
complex stimulation. These results are intriguing since C. pacifica 
KMM 3879T LPS was composed of a mixture of tetra‐, penta‐, and 
even hexa‐acylated lipid A species with this latter form considered 
as the typical immunostimulant ligand of the TLR4/MD‐2 complex. 
Notwithstanding, evident structural differences between E. coli 
LPS and C. pacifica KMM 3879T LPS may be responsible for the 
different immunological properties observed. Indeed, the 
presence of acyl chains shorter than those of E. coli (10 and 12 
carbon atoms vs. 14 and 12 carbon atoms) as well as the 
symmetric distribution of the acyl moieties of C. pacifica KMM 
3879T lipid A (3+3 symmetry, in its hexa-acylated form, vs. 4+2 
symmetry of E. coli lipid A) can be considered at the basis of the 
weak capability of C. pacifica KMM 3879T LPS to engage the 
TLR4/MD-2/CD14 pathway. Even more appealing was the 
observation of the potent inhibitory activity exhibited by C. pacifica 
KMM 3879T LPS towards the toxic effects of E. coli LPS on the 
human TLR4/MD‐2 complex. This fascinating property has been 
extensively reported for tetra‐acylated lipid A, such as lipid IVA,[18] 
and also for some other marine bacteria such as Halomonas 
megadiensis[19] and Halobacteroides lacunaris[20] as well as for 
the thermophilic bacterium Thermomonas hydrothermalis.[21] The 
TLR4/MD‐2 inhibitory action of C. pacifica KMM 3879T LPS may 
be justified by the occurrence of hypo‐acylated lipid A species, 
namely tetra‐ and penta‐acylated, in addition to the hexa‐acylated 
forms, thus resulting in a very weak elicitation of an immune 
response but maintaining the capability to robustly compete with 
the toxic E. coli LPS for binding to the TLR4/MD‐2 complex.  
In summary, this work certainly confirmed that, besides the 
peculiar structural features of C. pacifica KMM 3879T LPS, the 
exploration of marine bacteria LPS is a fundamental choice to 
screen for lipid A structures that may be of inspiration for 
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developing analogues with an immunomodulatory action on the 
immune system. 
Experimental Section 
Bacteria Isolation and Growth 
Bacteria were isolated from a sandy sediment sample collected at a 
depth of 1 m from the shore of the Sea of Japan, Russia. The bacterium 
was cultivated for 48 h at ambient temperature on the medium consisting 
of (L-1): 5.0 g bactopeptone, 2.5 g yeast extract, 1.0 g glucose, 0.2 g 
K2HPO4, 0.05 g MgSO4, and 750 mL natural seawater/250 mL distilled 
water.  
 
Extraction and purification of the LPS from C. pacifica KMM 3879T 
Dried cells were extracted by the hot phenol/water procedure[11] and the 
extracted material was dialyzed against distilled water. The nature of the 
extracted material was screened by an SDS‐PAGE followed by silver 
nitrate gel staining[12] that confirmed the smooth nature of the isolated LPS. 
To remove cell contaminants, such as proteins and nucleic acids, an 
enzymatic treatment with RNase (Sigma-Aldrich, Darmstadt, Germany), 
DNase (Sigma-Aldrich, Darmstadt, Germany), and Proteinase K (Sigma-
Aldrich, Darmstadt, Germany) (37 °C and 56 °C) was executed, followed 
by exhaustive dialysis against distilled water. Further steps of purification 
were executed, namely an ultracentrifugation (4 °C, 100,000 × g, 16 h) 
and a size-exclusion chromatography on a Sephacryl High Resolution S-
300 (GE Healthcare, Little Chalfont, UK) column. 
 
Chemical analyses 
The monosaccharide content was established by analysis of the 
acetylated O-methyl glycoside derivatives obtained by treatment with 
HCl/MeOH (1.25 M, 85 °C) followed by acetylation with acetic anhydride in 
pyridine (85 °C, 30 min).[22] The total fatty acid content was defined on 
intact LPS after hydrolysis with HCl (4 M, 100 °C, 4 h) followed by a 
neutralization step with NaOH (5 M, 100 °C, 30 min). The fatty acids were 
extracted in chloroform and then methylated with diazomethane. The 
absolute configuration of acyl chains was determined as previously 
described.[23] Authentic 3-hydroxy fatty acids were used to assign the (R) 
configuration to the LPS fatty acids. The obtained derivatives of sugars 
and fatty acids were analyzed by means of gas-liquid chromatography 
(GLC-MS) Agilent Technologies 6850A (Santa Clara, CA, USA) equipped 
with a mass selective detector 5973N and a Zebron ZB‐5 capillary 
column (Phenomenex, 30 m × 0.25 mm i.d., 0.25 μm as film thickness, 
flow rate 1 mL/min, He as carrier gas) and using the temperature program 
140 °C for 3 min, 140 °C/240 °C at 3 °C/min. 
 
Isolation of the lipid A fraction from C. pacifica KMM 3879T LPS 
In order to study the lipid A structure, an aliquot (30 mg) of pure LPS 
underwent a treatment with acetate buffer (pH 4.4) for 3 h at 100 °C under 
magnetic stirring. A mixture of chloroform and methanol was added to the 
hydrolysate to reach a chloroform/ methanol/hydrolysate 2:2:1.8 (v/v/v) 
ratio. The mixture was then shaken and centrifuged. The chloroform phase, 
containing the lipid A fraction, was collected and washed with the water 
phase of a freshly prepared Bligh/Dyer mixture (chloroform/ 
methanol/water, 2:2:1.8).[24] The organic phases were pooled, dried and 
analyzed by MALDI MS.  
Finally, an aliquot of the pure lipid A was also treated with 10 % NH4OH as 
previously described and analyzed by MALDI MS.[15] 
An aliquot of bacterial pellet underwent the lipid A micro-extraction 
procedure as previously reported.[13] 
  
MALDI mass spectrometry 
Micro-extracted lipid A was analyzed on a AB SCIEX TOF/TOFTM 5800 
Applied Biosystems mass spectrometer. All others MALDI MS and MS/MS 
spectra were executed on a 4800 Proteomic analyzer (SCIEX, Concord, 
ON, Canada) supplied with a Nd:YAG laser (wavelength of 355 nm). Lipid 
A preparations were performed as previously described.[25,26,27] Briefly, the 
sample was dissolved in CHCl3/CH3OH (50:50 v/v) whereas the matrix 
solution was trihydroxyacetophenone (THAP) dissolved in CH3OH/0.1 % 
TFA/CH3CN (7:2:1 v/v/v) at a concentration of 75 mg/mL. The ammonium 
hydroxide treated lipid A was prepared as previously described.[15] A 
sample/matrix solution mixture (1:1 v/v) was deposited (1 μL) onto a 100-
sample MALDI probe tip, and left to dry at room temperature. Mass 
accuracy was found below 75 ppm. 2000 laser shots were approximately 
accumulated for each mass spectrum, whereas 4000/6000 shots were 
summed for MS/MS acquisitions.  
 
BMDMs isolation, culture and stimulation  
C57BL/6 mice were purchased from Charles River (Charles River ITALY). 
BMDMs were derived from the bone marrow cells collected from five-week 
old female mice, as already reported.[28] Animal studies were conducted 
according to protocols approved by the University of Rome La Sapienza 
and adhered strictly to the Italian Ministry of Health guidelines for the use 
and care of experimental animals. Subsequently, BMDMs were 
differentiated during 5 days in RPMI1640 (Lonza, Italy), supplemented with 
10 % FBS (Hyclone, U.S.), 1 % Glutamine (Lonza, Italy), 1 % Na pyruvate 
(Lonza, Italy), 1 % NEAA (Lonza, italy), 0.5 % 2-ME (Gibco, Italy), and 30 
ng/mL macrophage colony-stimulating factor (M-CSF; Miltenyi Biotec). For 
the stimulation assay BMDMs were seeded into 24-well plates (5 x 105 
cells per well) and were exposed to different concentrations of C. pacifica 
KMM 3879T or E. coli LPS O111:B4 (1, 10, or 100 ng/mL) (INVIVOGEN) 
for 18 h. After this time the supernatant was removed and the level of TNF-
α measured through ELISA 
 
Human PMBCs differentiation and stimulation 
PBMCs were isolated from buffy coats obtained by the blood bank of 
Sapienza University from healthy adult volunteers (blood donors) following 
written informed consent. PBMC were obtained through a density gradient. 
CD14+ monocytes were isolated using the MACS microbead system 
(Miltenyi Biotec, Bergisch Gladbach, Germany). The monocytes were 
cultured for 6 days in RPMI 1640 (Lonza) supplemented with 10 % heat-
inactivated FBS (Euroclone Fetal Bovine Serum, GE Healthcare Life 
Sciences,U.S.), 100 µM non-essential amino acids, 1 mM sodium pyruvate, 
1000 U/ml penicillin and 1000 U/mL streptomycin (all from Lonza, Italy). 
For LPS stimulation the cells were seeded in 24-well plates (2,5 x 105 
cells/well, exposed to 1, 10 or 100 ng/mL of LPS derived from C. pacifica 
KMM 3879T or commercial E. coli O111:B4 for 18 h. Cell supernatants 
were recovered and processed for ELISA. For the competition assays, 
PBMCs cells were exposed to LPS (1, 10 and 100 ng/mL) of C. pacifica 
KMM 3879T together with 10 ng/mL of E. coli LPS for 18 hours. After this 
time, TNF-α production was measured. 
 
Cytokine measurement 
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Murine and human TNF-α and human CXCL-8 were determined in 
supernatants of stimulated BMDMs by using R&D Systems DuoSet ELISA 
kits according to the manufacturers’ instructions.  
 
Cell cultures  
The stably transfected human embryonic kidney epithelial cell line HEK 
293-hTLR4/MD2-CD14 (InvivoGen) were cultured in DMEM with 10 % 
FBS (Eurclone), 10 μg/mL Blasticidin-S and 50 μg/ml HygroGold® (both 
by InvivoGen). 
 
HEK 293-hTLR4/CD14/MD2 cell culture, transfection and stimulation 
Stably transfected cell line HEK 293-hTLR4/MD2-CD14 were seeded into 
96-well plates at the concentration of 1 x 105 cells/mL. The next day cells 
were transiently transfected with PolyFect Transfection Reagent (Qiagen) 
with a reaction mix composed by 150 ng of Firefly luciferase reporter 
constructs, pGL3.ELAM.tk (containing NF-κB promoter sequences), and 
15 ng of Renilla luciferase reporter plasmid, pRLTK (as an internal control). 
Twenty-four hours post-transfection cells were untreated or incubated with 
different concentrations (1, 10 and 100 ng/mL) of LPS of C. pacifica KMM 
3879T or of purified E. coli LPS (LPS-EB ultrapure; InvivoGen) for 6 h to 
analyze NF-κB activity and to measure CXCL-8 release. For the 
competition assays, HEK 293-TLR4/MD2-CD14 cells were primed with 
LPS (1, 10 and 100 ng/mL) of C. pacifica KMM 3879T for 1 hour and then 
stimulated with 10 ng of E. coli LPS for 4 hours. After this time, NF-κB 
activity and CXCL-8 production were measured. 
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Figure Legends 
 
Figure 1. Reflectron MALDI mass spectrum, recorded in negative polarity, of the micro-extracted lipid A from C. 
pacifica KMM 3879T LPS. Only deprotonated ions [M-H]- are formed in these conditions. The lipid A species are 
indicated. 
 
Figure 2. MALDI MS/MS spectrum of the hexa-acylated lipid A species at m/z 1628.0 from C. pacifica KMM 3879T 
LPS. Fragment assignments are reported. The proposed structure for the hexa-acylated lipid A species is reported 
in the inset. 
 
Figure 3. MALDI MS/MS spectrum of the tetra-acylated lipid A species at m/z 1275.7 from C. pacifica KMM 3879T 
LPS. Fragment assignments are reported. The proposed structures for the tetra-acylated lipid A species is reported 
in the inset. 
 
Figure 4. Negative ion MALDI mass spectrum of the lipid A from C. pacifica KMM 3879T LPS obtained from 10 % 
NH4OH hydrolysis. The proposed structures of the product are reported in the figure. 
 
Figure 5. MALDI MS/MS spectrum of tetra-acylated lipid A species at m/z 1151.7 from ammonium-hydroxide 
treated C. pacifica KMM 3879T lipid A.  
 
Figure 6. The proposed structure of the hexa-acylated lipid A species from C. pacifica KMM 3879T LPS. 
 
Figure 7. TNF-α release in macrophages stimulated with LPS of C. pacifica KMM 3879T. a) Bone-marrow-derived 
macrophages (BMDMs) from wild-type C57BL/6 mice were stimulated with the LPS of C. pacifica KMM 3879T or 
E. coli (0111:B4) at concentration of 1, 10, and 100 ng/mL. b) Human peripheral blood mononuclear cells (PBMCs) 
were stimulated with 10 ng/mL, 1 ug/mL and 10 ug/mL of C. pacifica KMM 3879T LPS, or E. coli O111:B4 at 
concentrations of 1, 10 and 100 ng/mL. Significant difference between the LPSs is indicated by *p < 0.05, **p < 
0.01, ***p < 0.001 by the Student’s t-test. 
 
Figure 8. Stimulation of HEK 293‐hTLR4/MD‐2/CD14. Fold of activation of NF‐κB (a) and CXCL-8 (b) upon 
stimulation with 1, 10, and 100 ng/mL with LPS of C. pacifica KMM 3879T; E. coli (0111:B4) was used as a control. 
Significant difference between C. pacifica KMM 3879T LPS generated values and the corresponding E. coli LPS 
values are indicated (C. pacifica KMM 3879T LPS vs. E. coli LPS) (*p < 0.05, **p < 0.01, ***p < 0.001). 
 
Figure 9. Competition assay. (a) Fold of NF‐κB activation and (b) CXCL-8 release in HEK 293-hTLR4/MD‐2/CD14 
stimulated with different concentrations (1, 10, and 100 ng/mL) of C. pacifica KMM 3879T LPS and then re‐
stimulated with 10 ng/mL of E. coli LPS. Significant difference between the LPSs is indicated by *p < 0.05, **p < 
0.01, ***p < 0.001 by the Student’s t-test. 
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Figure 1 
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Figure 2 
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Figure 3 
 
 
 
 
  
500 660 820 980 1140 1300
Mass (m/z)
0
10
20
30
40
50
60
70
80
90
100
%
 I
n
te
n
si
ty
1059.5
1060.4
961.5
979.5 1075.5
963.4
1057.6
654.3
- 12 (3:OH)
- 12:0
- H3PO4
- H3PO4
Y1
Precursor ion m/z 1275.7
Y1
10.1002/ejoc.201800279
Ac
ce
pt
ed
 M
an
us
cr
ip
t
European Journal of Organic Chemistry
This article is protected by copyright. All rights reserved.
FULL PAPER    
 
 
 
 
 
Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
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Figure 8 
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Figure 9 
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The structural and bioactivity 
elucidation of LPS from marine 
bacteria is an appealing research field 
from the perspective of conception of 
new generation drugs. Here we show 
that Cobetia pacifica KMM 3879T LPS 
expresses a complex family of lipid A 
species. Immunology studies on the 
LPS highlighted a low immunoactivity 
and a good inhibitory action towards 
toxic LPS. 
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